In order to properly utilize cancer therapies for personalized care, adequate molecular testing must be performed in patients who are eligible for these therapies, with this necessity becoming more and more prevalent in the treatment of gastrointestinal malignancies.
The recent advances in immunotherapy have revolutionized cancer care and ushered in an era of true precision medicine. But to best utilize these extraordinary therapies, oncologists must be able to recognize specific biomarkers and oncologic drivers associated with an individual patient’s cancer diagnosis. This is true, in particular, for oncologists specializing in the care of gastrointestinal (GI) cancers.
In this issue of ONCOLOGY®, we spoke with John L. Marshall, MD, director of the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center as well as cochair of the 6th Annual School of Gastrointestinal Oncology® (SOGO®), hosted by Physicians’ Education Resource, LLC (PER®), about the rise of molecular profiling in GI cancer.